MHRA approves Yorvipath (palopegteriparatide) to treat chronic hypoparathyroidism
Ascendis Pharma has announced that its drug Yorvipath has been approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) for the treatment of chronic hypoparathyroidism in adults – A condition that causes cramps and spasms due to low levels of calcium and PTH
“With today’s MHRA approval of Yorvipath, we are expanding our global geographic reach to meet the needs of adults with chronic hypoparathyroidism in Great Britain,” said Camilla Harder Harvig, EVP and chief commercial officer at Ascendis Pharma,
Yorvipath, formerly also known as Transcon PTH, is already approved in the EU, while the company also had a new marketing authorization application accepted by the FDA late last year after previously being rejected. The FDA is expected to decide on a US approval by May 14 this year. In addition, Yorvipath is also making its way to the market via partners Teijin Limited in Japan and Visen Pharmaceuticals in China.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins